Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Catalent, Inc.CTLT · Entity 16279 | EVP & Chief Financial Officer | August 24, 2017 | August 28, 2017 |
| Certara, Inc.CERT · Entity 787 | Director | May 14, 2026 | May 15, 2026 |
| MULTI COLOR CorpLABL · Entity 156212 | Director | October 03, 2016 | October 05, 2016 |
| Organon & Co.OGN · Entity 4115 | Chief Financial Officer | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Catalent, Inc.
Report date August 24, 2017 · Filed August 28, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 103,703 |
Last balance in matching sequence
After 2017-08-24 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-08-24 · Grant · Acquired 16,191 · Balance 111,948 F1: Received upon the achievement of the fiscal 2015-17 performance-based vesting criteria set forth in certain performance share units held by the reporting person. F2: Includes restricted stock units. Row 2 · 2017-08-24 · Tax withholding · Disposed 8,245 · Balance 103,703 F2: Includes restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Received upon the achievement of the fiscal 2015-17 performance-based vesting criteria set forth in certain performance share units held by the reporting person.
F2: Includes restricted stock units.
Certara, Inc.
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 213,316 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Exercise / conversion · Acquired 15,757 · Balance 213,316 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Exercise / conversion · Disposed 15,757 · Balance 0 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 33,222 |
Reported balance
After 2026-05-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-14 · Grant · Acquired 33,222 · Balance 33,222 F2: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.
F2: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting.
MULTI COLOR Corp
Report date October 03, 2016 · Filed October 05, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,854 |
Reported balance
After 2016-10-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-10-03 · Grant · Acquired 994 · Balance 1,854 F1: Restricted stock granted pursuant to Multi-Color's 2012 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock granted pursuant to Multi-Color's 2012 Stock Incentive Plan.
Organon & Co.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 212,746 |
Ending reported balance
After 2026-03-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-31 · Exercise / conversion · Acquired 12,047 · Balance 202,707 Row 2 · 2026-03-31 · Tax withholding · Disposed 4,127 · Balance 198,580 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Row 3 · 2026-03-31 · Exercise / conversion · Acquired 21,546 · Balance 220,126 Row 4 · 2026-03-31 · Tax withholding · Disposed 7,380 · Balance 212,746 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 321,368 |
Reported balance
After 2026-03-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-31 · Grant · Acquired 321,368 · Balance 321,368 F2: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 83,472 |
Reported balance
After 2026-03-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-31 · Grant · Acquired 83,472 · Balance 83,472 F3: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-31 · Exercise / conversion · Disposed 12,047 · Balance 0 F4: Each RSU represents a contingent right to receive one share of Organon common stock. F5: On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 43,094 |
Reported balance
After 2026-03-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-03-31 · Exercise / conversion · Disposed 21,546 · Balance 43,094 F4: Each RSU represents a contingent right to receive one share of Organon common stock. F6: On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
F2: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
F3: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
F4: Each RSU represents a contingent right to receive one share of Organon common stock.
F5: On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
F6: On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allergan plc
Report date May 08, 2020 · Filed May 12, 2020
Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-08 · Disposition to issuer · Disposed 12,039 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. |
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-05-08 · Disposition to issuer · Disposed 27,618 · Balance 0 F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-08 · Disposition to issuer · Disposed 28,021 · Balance 0 F3: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
F2: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.
F3: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 15, 2026 20:25 UTC | Certara, Inc. CERT · Entity 787 | GrantRestricted Stock Units · Derivative | 33,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001269428-26-000002 · form4-05152026_080529.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,222 Underlying: Common Stock · 33,222 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.exercise_date: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.expiration_date: Each RSU was granted on May 14, 2026, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:25 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionRestricted Stock Units · Derivative | 15,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001269428-26-000002 · form4-05152026_080529.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,757 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:25 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionCommon Stock | 15,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001269428-26-000002 · form4-05152026_080529.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 21,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · derivative · entry 8 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,094 Underlying: Common Stock · 21,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F6 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 12,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · derivative · entry 7 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,047 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F5 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 83,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · derivative · entry 6 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,472 Underlying: Common Stock · 83,472 shares Expires not disclosed F3 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F3 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F3 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 321,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · derivative · entry 5 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,368 Underlying: Common Stock · 321,368 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 7,380 | $5.70 | $42,066.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · nonDerivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,746 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 21,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · nonDerivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,127 | $5.70 | $23,523.90 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,580 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 12,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 15,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022377 · wk-form4_1774987616.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,071 Underlying: Common Stock · 15,071 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F3 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F3 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:06 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 5,162 | $5.84 | $30,146.08 |
DisclosureSEC source: 0001628280-26-022377 · wk-form4_1774987616.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,660 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 15,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022377 · wk-form4_1774987616.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:01 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,117 | $7.23 | $29,765.91 |
DisclosureSEC source: 0001628280-26-014228 · wk-form4_1772582504.xml · nonDerivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,751 F3 · balance_after: Includes the addition of 652 shares of Common Stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:01 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 12,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014228 · wk-form4_1772582504.xml · nonDerivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,216 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:01 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 14,887 | $7.17 | $106,739.79 |
DisclosureSEC source: 0001628280-26-014228 · wk-form4_1772582504.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,196 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:01 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 42,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014228 · wk-form4_1772582504.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,083 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 11, 2023 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:07 UTC | Certara, Inc. CERT · Entity 787 | GrantRestricted Stock Units · Derivative | 15,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014194 · form4-05222025_090526.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,757 Underlying: Common Stock · 15,757 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.exercise_date: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.expiration_date: Each RSU was granted on May 21, 2025, under the 2020 Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:07 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionRestricted Stock Units · Derivative | 11,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014194 · form4-05222025_090526.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:07 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionCommon Stock | 11,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014194 · form4-05222025_090526.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") was granted on May 21, 2024, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2025, the day of the issuer's annual meeting. Read SEC document |
| May 05, 2025 Filed May 6, 2025 17:59 UTC | Organon & Co. OGN · Entity 4115 | PurchaseCommon Stock | 11,400 | $8.82 | $100,548.00 |
DisclosureSEC source: 0001821825-25-000027 · wk-form4_1746554362.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,484 Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 7,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · derivative · entry 11 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,754 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F7 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F7 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 12,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · derivative · entry 10 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,047 Underlying: Common Stock · 12,046 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. F6 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 15,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · derivative · entry 9 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,142 Underlying: Common Stock · 15,070 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 64,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · derivative · entry 8 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,640 Underlying: Common Stock · 64,640 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 317,656 | $0.00 Strike: $14.89 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · derivative · entry 7 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,656 Underlying: Common Stock · 317,656 shares Expires not disclosed F2 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. F2 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 3,819 | $14.51 | $55,413.69 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 6 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,084 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 7,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 5 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 5,933 | $14.51 | $86,087.83 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,149 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 12,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 7,422 | $14.51 | $107,693.22 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,036 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 15,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000014 · wk-form4_1743630106.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:09 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,908 | $15.29 | $29,173.32 |
DisclosureSEC source: 0001821825-25-000004 · wk-form4_1740434946.xml · nonDerivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,388 Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:09 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 5,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000004 · wk-form4_1740434946.xml · nonDerivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,296 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:09 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 10,662 | $14.92 | $159,077.04 |
DisclosureSEC source: 0001821825-25-000004 · wk-form4_1740434946.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,726 Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:09 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 30,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000004 · wk-form4_1740434946.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,388 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 09, 2022 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:31 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 3,541 | $20.35 | $72,059.35 |
DisclosureSEC source: 0001821825-24-000098 · wk-form4_1725568268.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,974 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:31 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 7,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000098 · wk-form4_1725568268.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,515 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:45 UTC | Certara, Inc. CERT · Entity 787 | GrantRestricted Stock Units · Derivative | 11,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014298 · form4-05232024_080552.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,928 Underlying: Common Stock · 11,928 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.exercise_date: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. F2 · derivative.expiration_date: Each RSU was granted on May 21, 2024, under the Incentive Plan that entitles the reporting person to receive one share of issuer's common stock per RSU. The RSUs vest on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual meeting. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:45 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionRestricted Stock Units · Derivative | 8,663 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014298 · form4-05232024_080552.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:45 UTC | Certara, Inc. CERT · Entity 787 | Exercise / conversionCommon Stock | 8,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014298 · form4-05232024_080552.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") was granted on May 23, 2023, under Certara, Inc.'s 2020 Incentive Plan ("Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 21, 2024, the day of the issuer's annual meeting. Read SEC document |
| May 04, 2024 Filed May 7, 2024 20:05 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 8,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000058 · wk-form4_1715112284.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,310 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. Read SEC document |
| May 04, 2024 Filed May 7, 2024 20:05 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,093 | $19.61 | $80,263.73 |
DisclosureSEC source: 0001821825-24-000058 · wk-form4_1715112284.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,326 Read SEC document |
| May 04, 2024 Filed May 7, 2024 20:05 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 8,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000058 · wk-form4_1715112284.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:42 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 12,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000049 · wk-form4_1712184118.xml · derivative · entry 6 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,093 Underlying: Common Stock · 12,046 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F3 · derivative.exercise_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. F3 · derivative.expiration_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:42 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 7,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000049 · wk-form4_1712184118.xml · derivative · entry 5 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,754 Underlying: Common Stock · 7,753 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:42 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 5,933 | $18.80 | $111,540.40 |
DisclosureSEC source: 0001821825-24-000049 · wk-form4_1712184118.xml · nonDerivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,109 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:42 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 12,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000049 · wk-form4_1712184118.xml · nonDerivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:42 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 3,819 | $18.80 | $71,797.20 |
DisclosureSEC source: 0001821825-24-000049 · wk-form4_1712184118.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,996 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.